Diflomotecan
Diflomotecan (BN 80915) is a potent and orally active inhibitor of topoisomerase I. Diflomotecan (BN 80915) causes enhanced plasma stability and has the superior preclinical anti-tumour activity compared with other established compounds.
For research use only. We do not sell to patients.
- CAS No.: 220997-97-7
- Formula: C21H16F2N2O4
- Molecular Weight:398.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Topoisomerase Isoforms
More
Biological Activity
topoisomerase I[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
3.4 nM
Compound: 12
|
Cytotoxicity against human A549 cells by WST assay
Cytotoxicity against human A549 cells by WST assay
|
[PMID: 23578545] |
| A549 | IC50 |
3.4 nM
Compound: 8f
|
Cytotoxicity against A549 tumor cell line determined by WST-1 assay
Cytotoxicity against A549 tumor cell line determined by WST-1 assay
|
[PMID: 10841808] |
| HT-29 | IC50 |
8.4 nM
Compound: 8f
|
Cytotoxicity against HT-29 tumor cell line determined by WST-1 assay
Cytotoxicity against HT-29 tumor cell line determined by WST-1 assay
|
[PMID: 10841808] |
| T-24 | IC50 |
0.4 nM
Compound: 12
|
Cytotoxicity against human chemo-resistant T24 cells by WST assay
Cytotoxicity against human chemo-resistant T24 cells by WST assay
|
[PMID: 23578545] |
| T-24 | IC50 |
0.4 nM
Compound: 8f
|
Cytotoxicity against T24 tumor cell line determined by WST-1 assay
Cytotoxicity against T24 tumor cell line determined by WST-1 assay
|
[PMID: 10841808] |
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 220997-97-7
-
Molecular Weight 398.36
-
Formula C21H16F2N2O4
-
SMILES
O=C(OC1)C[C@](O)(CC)C2=C1C(N3CC4=CC5=CC(F)=C(F)C=C5N=C4C3=C2)=O
-
Synonyms
BN 80915
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Kroep JR, et al. Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Investig Drugs. 2009;18(1):69-75. [Content Brief]
[2]. Gelderblom H, et al. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res. 2003;9(11):4101-4107. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)